|View printer-friendly version|
|Visualant Announces Shareholder Update|
I am pleased to update you on
I would like to begin by reviewing the basics of Visualant’s award-winning technology and highlighting some of its compelling attributes and broad applications.
Almost everything in nature has a unique chromatic signature. Visualant’s award-winning technology, ChromaID, uses light to authenticate, identify and diagnose a wide variety of matter with accuracies at the wavelength of a photon. Traditional methods require the use of specialized and bulky equipment such as spectrophotometers and complex laboratory analysis which adds cost and time.
ChromaID is a platform technology that simplifies this process with its pioneering method of using structured light, a disruptive breakthrough in photonics, harnessing the power of the spectrophotometer into a handheld device at a competitive price.
Using a patented technology that includes a series of frequency-specific light-emitting diodes (LEDs), ChromaID creates a unique chromatic signature with thousands of data points providing a high degree of accuracy in a fraction of a second. This allows for instantaneous identification and analysis; saving time and increasing productivity.
The Company currently has 10 issued patents and 20 patents pending on our current technology and its applications. As we have previously announced, we have patents pending relating to everything from food safety, to diamond grading, to ascertaining blood glucose levels. ChromaID technology can be used to authenticate anything from manufactured goods, driver’s licenses and access cards, pharmaceuticals and beyond. ChromaID can identify e-Coli on meat, explosive residue on a terrorist’s hand and counterfeit currency.
ChromaID, as mentioned above, is also a sensor technology which exists
in the environment known as the
There are other potential developments underway which we will be able to announce over time as we seek development partners to expand the reach and markets for our ChromaID technology
The Company’s commercialization plan includes three priorities for 2017: continue to mature the technology, expand our work in security applications and add commercialization partners. The Company plans to produce a next generation ChromaID system that will build on the success of the previous model while incorporating the feedback we have received from potential customers. Potential customers have asked for enhancements that will better demonstrate how the ChromaID will work in their applications. The Company believes it can incorporate these enhancements at a relatively low cost and that these enhancements will speed the path to commercialization.
Events impacting the growth of our business over the past year and
beyond include our Joint Development Agreements with
Intellicheck and BIOMEDX are two relationships providing opportunities
Our team was also enhanced late this past year with the additions of
We are appreciative of the support from those of you who are long term
shareholders. We want you to know that we are committed to the long-term
Thank you for your support of the Company. Please do not hesitate to be in touch with me. I would love to hear from you.
Visualant™ is a public company whose shares trade under the stock symbol
“VSUL.” The Visualant Spectral Pattern Matching™ (SPM) technology
directs structured light onto a substance or material, through a liquid
or gas, or off a surface, to capture a unique ChromaID™. A ChromaID can
be used to identify, detect, or diagnosis markers invisible to the human
eye. ChromaID scanner modules can be integrated into a variety of mobile
or fixed-mount form factors. The patented, award-winning technology is
disruptive, making it possible to effectively conduct analyses in the
field that could only previously be performed by large and expensive
lab-based tests. For more information on
Safe Harbor Statement
"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995: This press release contains forward-looking statements
(within the meaning of Section 27a of the Securities Act of 1933 and
Section 21e of the Securities Exchange Act of 1934) regarding us and our
business, financial condition, results of operations and prospects.
Forward-looking statements in this press release reflect the good faith
judgment of our management and are based on facts and factors currently
known to us. Forward-looking statements are subject to risks and
uncertainties, and actual results and outcomes may differ materially
from the results and outcomes discussed in the forward-looking
statements as a result of either the matters set forth or incorporated
in this press release generally or certain economic and business
factors, some of which may be unknown to and/or beyond the control of